Research
Inositol (Myo-Inositol)
152 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials.
This umbrella review synthesized meta-analyses of RCTs to evaluate the efficacy of inositol for PCOS. Inositol significantly improved hormonal profiles, glycolipid metabolism, and reproductive outcomes compared to placebo, but showed limited effects compared to metformin. The review highlights moderate-quality evidence supporting inositol's benefits, though outcomes based on low-quality evidence require cautious interpretation.
Effect of myo-inositol supplementation in mixed ovarian response IVF cohort: a systematic review and meta-analysis.
Systematic review and meta-analysis of 11 studies with 981 participants investigating the effect of myo-inositol on IVF outcomes. Results showed that myo-inositol supplementation improved the metaphase II oocyte rate and fertilization rate, particularly in women with PCOS and non-obese PCOS, but not in poor ovary responders.
Infant body composition in a randomised trial of a maternal nutritional supplement during preconception and pregnancy.
Multinational RCT examining the effects of maternal supplementation with myo-inositol, probiotics, and micronutrients on infant body composition. No group-level differences in body composition were found, except at two years where control offspring had greater fat-free mass. Fewer offspring from the supplemented group experienced rapid weight gain and high BMI.
Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
This randomized clinical trial investigated the effect of myo-inositol supplementation on pregnancy complications in individuals with PCOS. The study found that myo-inositol did not significantly reduce the incidence of gestational diabetes, preeclampsia, or preterm birth compared to placebo.
The role of the myo-inositol for the prevention of the gestational diabetes: systematic review.
Systematic review evaluating the effectiveness of myo-inositol supplementation in pregnant women at high risk for Gestational Diabetes Mellitus (GDM). Myo-inositol significantly decreased GDM incidence in all included studies, with some studies noting additional benefits such as weight loss and reduced hypertensive disorders.
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines.
Systematic review and meta-analysis evaluating the efficacy of inositol in managing PCOS. Evidence suggests benefits for myo-inositol or D-chiro-inositol for some metabolic measures and potential benefits for ovulation, but inositol may have no effect on other outcomes. The evidence supporting inositol use in PCOS management is limited and inconclusive.
Comparative efficacy and safety of metformin, anti-obesity agents, and myoinositol in improving IVF/ICSI outcomes and reducing ovarian hyperstimulation syndrome in women with polycystic ovary syndrome: a systematic review and network meta-analysis.
Systematic review and network meta-analysis comparing metformin, anti-obesity agents, and myoinositol in women with PCOS undergoing IVF/ICSI. Myoinositol and metformin reduced OHSS risk, but did not significantly improve pregnancy outcomes. Myoinositol was linked to shorter gonadotropin duration and fewer side effects, while metformin reduced E2 levels and increased mature oocytes but caused more side effects.
Effectiveness of Myo-Inositol on Oocyte and Embryo Quality in Assisted Reproduction: Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Systematic review and meta-analysis of RCTs evaluating the impact of myo-inositol on oocyte and embryo quality in women undergoing assisted reproduction. The analysis included 820 participants and found no significant benefits of myo-inositol on oocyte and embryo quality, miscarriage rate, or clinical pregnancy rates.
Maternal mood, anxiety and mental health functioning after combined myo-inositol, probiotics, micronutrient supplementation from preconception: Findings from the NiPPeR RCT.
The NiPPeR RCT investigated the effects of a myo-inositol, probiotics, and micronutrients supplement taken preconception and during pregnancy on mental wellbeing. No robust differences in mood and anxiety were found between intervention and control groups, but there was a modest improvement in mental health functioning from preconception to 6-months post-delivery.
Higher early pregnancy plasma myo-inositol associates with increased postprandial glycaemia later in pregnancy: Secondary analyses of the NiPPeR randomized controlled trial.
The NiPPeR randomized controlled trial examined the effects of myo-inositol supplementation starting preconception on gestational glycaemia in 585 women. Higher early pregnancy plasma myo-inositol was associated with increased postprandial glycaemia later in pregnancy, but did not affect gestational diabetes risk, birthweight, or cord C-peptide levels. The study suggests that the timing of myo-inositol supplementation may influence maternal metabolic adaptation.
Higher Plasma-Inositol in Pregnancy Associated with Reduced Postpartum Blood Loss: Secondary Analyses of the NiPPeR Trial.
Secondary analysis of the NiPPeR trial assessing the association of plasma inositol and various vitamins with postpartum blood loss (PBL) in 583 women. Higher inositol concentration in early pregnancy was associated with reduced PBL, suggesting inositol as a key component in the intervention's effect.
Impact of preconception and antenatal supplementation with myo-inositol, probiotics, and micronutrients on offspring BMI and weight gain over the first 2 years.
RCT of 576 offspring of women receiving preconception and antenatal supplementation with myo-inositol, probiotics, and micronutrients versus standard micronutrients. The intervention group showed trends towards lower BMI and reduced rapid weight gain in the first 2 years of life.
Comparison of metformin with inositol versus metformin alone in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of RCTs comparing combined metformin and inositol therapy versus metformin alone in women with PCOS. Combination therapy improved menstrual cycle regularity and reduced hirsutism and LH/FSH ratio, but showed no significant differences in acne, BMI, fasting blood glucose, and HOMA-IR.
Influence of myo-inositol on metabolic status for gestational diabetes: a meta-analysis of randomized controlled trials.
Meta-analysis of four RCTs with 317 patients assessing myo-inositol supplementation for gestational diabetes. Myo-inositol supplementation decreased the need for insulin treatment and improved HOMA-IR, but had no significant impact on birth weight, cesarean section rates, or NICU needs.
Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: an open-label, randomized controlled trial.
Open-label RCT of 200 pregnant women assessing myo-inositol supplementation on gestational diabetes mellitus (GDM) incidence. The myo-inositol group showed a significantly lower incidence of GDM and improved insulin sensitivity compared to the control group.
Myoinositols Prevent Gestational Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Systematic review and meta-analysis of RCTs investigating inositol supplementation in preventing gestational diabetes mellitus (GDM) and related outcomes. Inositols halved the incidence of GDM and significantly decreased OGTT glucose levels. Myoinositol reduced the risk of insulin need, preeclampsia, gestational hypertension, preterm birth, and neonatal hypoglycemia.
Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial.
Secondary outcomes of the NiPPeR RCT assessed the impact of a myo-inositol, probiotics, and micronutrient supplement on time-to-natural-conception and clinical pregnancy rates in women planning to conceive. Overall, time-to-conception and pregnancy rates were similar between intervention and control groups, but the supplement may shorten time-to-conception in overweight women.
Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of 26 RCTs involving 1691 patients with PCOS, comparing inositol to metformin and placebo. Inositol was found to be effective and safe, showing non-inferiority to metformin in cycle normalization and improvements in BMI, testosterone levels, and glucose metabolism.
Inositol supplementation for the prevention and treatment of gestational diabetes mellitus: a meta-analysis of randomized controlled trials.
Meta-analysis of 7 RCTs involving 1319 pregnant women at high risk of gestational diabetes mellitus (GDM) found that inositol supplementation significantly reduced the incidence of GDM, improved fasting glucose and oral glucose tolerance test results, and reduced the risk of pregnancy-induced hypertension and preterm birth. Inositol also lowered insulin resistance and neonatal hypoglycemia risk in GDM patients.
Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.
Meta-analysis of seven RCTs involving 1319 pregnant women assessing the effects of myo-inositol supplementation on preventing gestational diabetes. Myo-inositol may reduce the incidence of gestational diabetes, hypertensive disorders of pregnancy, and preterm birth, though the certainty of evidence is low to very low.
Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis.
Meta-analysis comparing the effects of myo-inositol and metformin on hormonal and metabolic parameters in women with PCOS. The analysis found no significant difference between the two substances in terms of BMI, fasting insulin, fasting blood sugar, HOMA index, and LH/FSH ratio.
The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis.
Systematic review and meta-analysis of six RCTs evaluating myo-inositol supplementation in overweight and obese pregnant women. The study suggests that 4 g myo-inositol per day may reduce the incidence of gestational diabetes mellitus, pregnancy-induced hypertension, and preterm delivery, but the certainty of evidence is low to very low. No adverse effects were noted.
The effect of a preconception and antenatal nutritional supplement on children's BMI and weight gain over the first 2 years of life: findings from the NiPPeR randomised controlled trial.
RCT examining the effect of preconception and antenatal supplementation with myo-inositol, probiotics, and additional micronutrients on children's BMI and weight gain over the first 2 years of life. The intervention was associated with a lower risk of rapid weight gain and high BMI at age 2 years.
Myoinositol or D-chiro-inositol for PCOS symptoms in adolescents: a narrative review.
Narrative review of studies on myoinositol or D-chiro-inositol for PCOS symptoms in adolescents. Eight studies included, showing improvements in some biochemical markers, metabolic parameters, or clinical symptoms, but results were not consistent across all studies. Highlights need for more robust research.
Effectiveness of five interventions used for prevention of gestational diabetes: A network meta-analysis.
Network meta-analysis of 46 RCTs involving 16,545 patients to assess interventions for preventing gestational diabetes mellitus (GDM). Physical activity and probiotic intervention significantly reduced GDM risk, while dietary intervention, combined physical activity and diet, and inositol supplementation did not significantly alter GDM risk.
Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis.
Systematic review and meta-analysis comparing the effects of metformin, inositol, and their combination on assisted reproductive technology outcomes in women with PCOS. Metformin improved clinical pregnancy rates and reduced ovarian hyperstimulation syndrome, while inositol showed higher clinical pregnancy rates compared to no treatment. The combination treatment was not eligible for meta-analysis.
Peripartum outcomes after combined myo-inositol, probiotics, and micronutrient supplementation from preconception: the NiPPeR randomized controlled trial.
The NiPPeR randomized controlled trial studied the effects of a combined myo-inositol, probiotics, and micronutrient supplement started at preconception on peripartum outcomes. The intervention reduced the duration of the second stage of labor, the risk of operative delivery for delay in the second stage, and blood loss at delivery.
Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Systematic review and meta-analysis of RCTs assessing inositol supplementation for preventing gestational diabetes mellitus (GDM). Seven RCTs with 1321 participants showed that 4 g myo-inositol per day significantly decreased GDM incidence and plasma glucose levels. No significant effects were observed with lower doses of inositol.
Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.
Meta-analysis of 17 randomized controlled trials with 1083 PCOS patients assessing the effect of myo-inositol on anthropometric, metabolic, and endocrine outcomes. No significant improvement was observed in most outcomes except androstenedione and prolactin levels.
Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials.
This meta-analysis evaluated the efficacy and safety of myo-inositol compared to metformin in treating women with polycystic ovary syndrome. Myo-inositol was found to be more effective in lowering triglyceride levels and avoiding side effects, with no significant differences in total testosterone and sex-hormone binding globulin levels.
The efficacy of myo-inositol supplementation to reduce the incidence of gestational diabetes: a meta-analysis.
This meta-analysis included eight RCTs to evaluate the efficacy of myo-inositol supplementation in reducing the incidence of gestational diabetes. Myo-inositol significantly decreased the incidence of gestational diabetes, 2-h glucose OGTT, HOMA-IR, and preterm delivery, but had no significant impact on gestational age at birth or birth weight.
Myo-inositol supplementation for the prevention of gestational diabetes: A meta-analysis of randomized controlled trials.
Meta-analysis of RCTs assessing myo-inositol supplementation for preventing gestational diabetes. Myo-inositol reduced the incidence of gestational diabetes, decreased 2-h glucose OGTT, increased gestational age at birth, and decreased preterm delivery incidence, but had no significant effect on birth weight.
Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature.
Systematic review of nutraceuticals for PCOS treatment, focusing on glucose and insulin metabolism, androgenic hormone profile, fertility, ovulatory capacity, inflammation, and oxidative stress. Inositols, particularly at a 40:1 ratio of myo- and D-chiro-inositols, were most effective for glucose homeostasis and fertility. Probiotics, vitamin D, vitamin E, and selenium showed benefits in reducing hyperandrogenism and improving inflammatory and oxidative conditions.
Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial
This double-blind RCT investigated the effects of a nutritional formulation containing myo-inositol, probiotics, and micronutrients on pregnancy outcomes in 1,729 women planning conception. The intervention did not lower gestational glycemia but reduced preterm birth rates compared to a standard micronutrient supplement.
Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Network meta-analysis comparing the efficacy of oral insulin sensitizers including inositols and berberine in women with PCOS. Myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones were superior to metformin alone in improving insulin resistance and decreasing total testosterone. Myo-inositol combined with D-chiro-inositol was particularly effective in menstrual recovery.
Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial.
RCT evaluating the 24-month neurodevelopmental outcomes of preterm infants enrolled in the NICHD Neonatal Research Network Inositol for Retinopathy Trial. The treatment group did not affect the risk for the composite outcome of death or survival with moderate/severe neurodevelopmental impairment.
The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis.
Systematic review and meta-analysis comparing the effects of myo-inositol and metformin on hormonal and metabolic profiles in PCOS patients. Myo-inositol showed potential improvements in fertility outcomes by modulating hyperandrogenism, though no significant differences were established between the two substances regarding hormonal profiles and ovarian function.
The effect of inositol supplementation on blood pressure: A systematic review and meta-analysis of randomized-controlled trials.
Systematic review and meta-analysis of 7 RCTs assessing the impact of inositol supplementation on blood pressure. The analysis found a significant decline in both systolic and diastolic blood pressure following inositol supplementation, particularly in individuals with metabolic syndrome over a longer duration and higher dose.
Effect of a Combination of Myo-Inositol, Alpha-Lipoic Acid, and Folic Acid on Oocyte Morphology and Embryo Morphokinetics in non-PCOS Overweight/Obese Patients Undergoing IVF: A Pilot, Prospective, Randomized Study
Pilot, prospective, randomized study assessing the effect of Myo-Inositol, Alpha-Lipoic Acid, and Folic Acid on oocyte quality and embryo development in non-PCOS overweight/obese women undergoing IVF. The combination showed a positive effect on oocyte morphology and embryo score, suggesting potential benefits for IVF outcomes.
Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial.
RCT evaluating myo-inositol supplementation in 223 overweight non-obese pregnant women. Myo-inositol significantly reduced the incidence of gestational diabetes mellitus and pregnancy-induced hypertension compared to placebo. Body water distribution was also more favorable in the myo-inositol group.
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation.
Systematic review of inositol supplementation in non-alcoholic fatty liver disease (NAFLD). Animal studies showed inositol deficiency increased fatty liver, while supplementation reduced hepatic triglycerides and cholesterol. One human RCT found pinitol reduced liver fat and improved liver markers.
The efficacy and safety of inositol supplementation in preterm infants to prevent retinopathy of prematurity: a systematic review and meta-analysis.
This systematic review and meta-analysis evaluated the efficacy and safety of inositol supplementation in preterm infants for preventing retinopathy of prematurity (ROP). The analysis included six studies with 1194 infants and found that inositol supplementation had no significant effect on the incidence of severe ROP or mortality. Sensitivity analysis indicated a trend toward increased mortality in the inositol group.
Inositol in preterm infants at risk for or having respiratory distress syndrome.
Systematic review of six RCTs with 1177 preterm infants assessing inositol supplementation for reducing adverse neonatal outcomes. Inositol supplementation did not significantly reduce rates of infant deaths, ROP, IVH, BPD, NEC, or sepsis. The review concludes that inositol should not be routinely used in preterm infants with or without RDS.
Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.
Meta-analysis comparing the short-term effects of metformin and myo-inositol in women with PCOS. No significant differences were found between the two treatments on fasting insulin, HOMA index, testosterone, SHBG levels, and BMI. Myo-inositol showed better tolerability with fewer adverse events compared to metformin.
Inositol for subfertile women with polycystic ovary syndrome.
This meta-analysis reviewed 13 trials involving 1472 subfertile women with PCOS receiving myo-inositol as pre-treatment to IVF or during ovulation induction. The evidence was of low to very low quality, with uncertainty about whether myo-inositol improves live birth or clinical pregnancy rates compared to standard treatment. The analysis also found uncertainty regarding its effect on miscarriage and multiple pregnancy rates.
Effects of inositol on glucose homeostasis: Systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of 20 RCTs with 1239 subjects assessing inositol supplementation on glucose homeostasis. Inositol reduced fasting plasma glucose, 2-hour post-OGTT glucose, abnormal glucose tolerance, fasting insulin, and HOMA-IR, indicating improved insulin sensitivity. No significant effects on BMI, HbA1c, or insulin treatment requirement were observed.
Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of RCTs assessing inositol supplementation during pregnancy for preventing gestational diabetes. Inositol was associated with a lower rate of gestational diabetes and preterm delivery, with significant effects observed in patients receiving 2g Myo-inositol twice daily.
Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.
Systematic review and network meta-analysis comparing the effectiveness of metformin, inositol, liraglutide, and orlistat for weight loss in women with PCOS and overweight/obesity. Liraglutide was found to be superior in reducing weight and waist circumference.
Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of RCTs evaluating myo-inositol supplementation in women undergoing IVF. Myo-inositol reduced the amount of gonadotropins and the length of ovarian stimulation, particularly in PCOS women.
Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of RCTs assessing the effectiveness of myo-inositol and d-chiro-inositol on oocyte or embryo quality and pregnancy rates in women with PCOS undergoing ICSI. MYO supplementation was insufficient to improve oocyte quality, embryo quality, or pregnancy rate.
Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET.
Meta-analysis and systematic review of seven trials with 935 women evaluating myoinositol supplementation in infertile women undergoing ovulation induction for ICSI or IVF-ET. Myoinositol was associated with improved clinical pregnancy rate, embryo quality, and reduced unsuitable oocytes and required stimulation drugs.
Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
Systematic review and meta-analysis of RCTs assessing myo-inositol supplementation in pregnant women at high risk of gestational diabetes mellitus (GDM). Myo-inositol significantly lowered the risk of developing GDM and reduced fasting, 1h, and 2h OGTT values. It did not significantly affect birth weight.
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis.
This meta-analysis assessed the effectiveness and safety of myoinositol for patients with PCOS, including data from 10 trials with 573 patients. Myoinositol improved the HOMA index and increased estradiol levels, but showed no strong evidence of affecting total testosterone levels. It may be recommended for treating PCOS with insulin resistance and improving symptoms related to decreased estrogen.
Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Meta-analysis of RCTs evaluating inositol as an ovulation induction agent in women with polycystic ovary syndrome. Inositol significantly improved ovulation rate and increased frequency of menstrual cycles compared with placebo. Evidence for pregnancy, miscarriage, or live birth is lacking.
Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies.
Meta-analysis of 20 RCTs involving 6,444 women assessing nutritional manipulation for preventing gestational diabetes mellitus (GDM). Diet-based interventions reduced GDM risk by 33%, while mixed diet and lifestyle interventions had no effect. Nutritional supplements, specifically myo-inositol and probiotics combined with diet, showed beneficial effects in reducing GDM risk.
Antenatal dietary supplementation with myo-inositol in women during pregnancy for preventing gestational diabetes.
Meta-analysis of four RCTs conducted in Italy assessing antenatal dietary supplementation with myo-inositol in 567 pregnant women for preventing gestational diabetes. Myo-inositol supplementation was associated with a reduction in the incidence of gestational diabetes compared to control, though evidence quality was low due to unclear risk of bias and lack of generalisability.
Relationship Between Myo-Inositol Supplementary and Gestational Diabetes Mellitus: A Meta-Analysis.
Meta-analysis of 5 trials with 513 participants assessing the effect of myo-inositol supplementation on gestational diabetes mellitus (GDM). Myo-inositol supplementation significantly reduced the incidence of GDM, birth weight, fasting glucose, and glucose levels during OGTT, suggesting a positive effect on women's health.
A meta-analysis of inositol for depression and anxiety disorders.
Meta-analysis of inositol as a treatment for depression and anxiety disorders, including 7 RCTs in depression and 4 RCTs in anxiety disorders. No statistically significant effects were found, but inositol showed marginally more responders in depression and a trend towards efficacy in PMDD. Inositol marginally caused gastrointestinal upset compared with placebo.
Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS Phenotypes: enhancing ovarian function, ovulation, and stress response in a prospective clinical trial.
This study compared the efficacy of Myo-inositol and D-chiro-inositol with metformin in enhancing ovarian function, promoting ovulation, and reducing stress in 60 women with PCOS. Both treatments improved insulin sensitivity, SHBG levels, ovarian volume, menstrual regularity, BMI, quality of life, and stress scores. Metformin showed slightly better outcomes in some parameters, but MI plus DCI may be more effective for certain PCOS phenotypes.
The ameliorative effect of myo-inositol on apoptosis-related genes expression in cumulus cells of women with polycystic ovary syndrome undergoing ICSI and its relationship with the quality of oocyte and embryo.
This placebo-controlled clinical trial investigated the effect of myo-inositol on apoptosis-related genes expression in cumulus cells of PCOS patients undergoing ICSI. Sixty infertile women with PCOS were assigned to receive either myo-inositol with folic acid or placebo. The MYO group showed increased expression of Survivin and Bcl-2 and decreased expression of Caspase-3, Caspase-7, and TNF-α, correlating with better embryo quality.
Efficacy of myo-inositol and zinc on insulin resistance in a paediatric population with obesity.
Double-blind, randomized, placebo-controlled study in North Italy assessing myo-inositol and zinc supplementation in 56 children with obesity and insulin resistance. The treatment improved HDL cholesterol levels and showed benefits in managing obesity complications, particularly in severe cases, but did not significantly affect insulin resistance.
Effect of Insulin Sensitizers on Glycemic and Lipid Profile in Patients with Polycystic Ovary Syndrome (PCOS).
Prospective randomized clinical study evaluating the impact of Metformin and Myoinositol on glycemic and lipid profiles in women with PCOS. Myoinositol improved cholesterol levels regardless of BMI, while Metformin significantly improved glycemic control in overweight patients.
Bipolar disorder in patients with psoriasis and the impact of lithium therapy on psoriasis.
Systematic review examining the relationship between bipolar disorder and psoriasis, and the impact of lithium therapy on psoriasis. The review highlights that lithium therapy may trigger or worsen psoriasis, and suggests that inositol supplementation could mitigate psoriasis in patients taking lithium.
Effectiveness of dual combination therapy of acarbose plus metformin and acarbose plus myo-inositol in ameliorating the metabolic and endocrinologic complications of polycystic ovary syndrome - A randomized controlled trial.
An open labelled RCT was conducted on 168 PCOS women to compare the effectiveness of acarbose plus metformin and acarbose plus myo-inositol combination therapy. Significant reductions in LH, LH: FSH, TT, and HOMA-IR were observed in all groups. The acarbose plus myo-inositol group showed significant increases in serum progesterone and reductions in FI, TGL, and LDL, contributing to cardio-metabolic safety in PCOS.
Improvement in biochemical manifestations of the serum and follicular fluid and ICSI outcomes in PCOS patients with myo-inositol administration: prospective randomized research.
Prospective randomized research on 60 infertile PCOS patients undergoing ICSI, comparing myo-inositol (MI) with placebo. The MI group showed significant improvements in hormonal profiles, oxidative stress markers, and embryo quality, indicating benefits for women with PCOS undergoing ART.
Clinical effectiveness of α-lipoic acid, myo-inositol and propolis supplementation on metabolic profiles and liver function in obese patients with NAFLD: A randomized controlled clinical trial.
RCT of 92 obese patients with NAFLD comparing the effects of alpha-lipoic acid, myo-inositol, and propolis supplementation on metabolic parameters and liver function over 8 weeks. Myo-inositol showed the greatest improvements in glycemic indices and cholesterol levels, while propolis significantly reduced ALT levels. All groups showed significant reductions in anthropometric measures.
Combined Inositols, α-Lactalbumin, Gymnema Sylvestre and Zinc Improve the Lipid Metabolic Profile of Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial
RCT on 75 patients with T2DM evaluating the effects of a combination of myo-inositol and d-chiro-inositol, α-lactalbumin, Gymnema sylvestre, and zinc on glucose and lipid profile. The study group showed reduced levels of total cholesterol and LDL, improved HDL and triglycerides, and greater body weight reduction compared to placebo.
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
RCT comparing metformin monotherapy to a combination of metformin with myoinositol and d-chiro-inositol in 53 overweight and obese women with PCOS. The myoinositol combination improved menstrual cycle regularity and quality of life more than metformin alone, though other hormonal and metabolic parameters showed no significant differences.
Beyond the Umbrella: A Systematic Review of the Interventions for the Prevention of and Reduction in the Incidence and Severity of Ovarian Hyperstimulation Syndrome in Patients Who Undergo In Vitro Fertilization Treatments.
Systematic review identifying interventions to prevent and reduce the incidence and severity of ovarian hyperstimulation syndrome (OHSS) in IVF patients. Inositol pretreatment, low doses of urinary hCG for ovulation triggering, and luteal phase administration of a GnRH antagonist may reduce OHSS risk.
Myo-inositol nutritional supplement for prevention of gestational diabetes (EMmY): a randomised, placebo-controlled, double-blind pilot trial with nested qualitative study.
This pilot RCT evaluated the feasibility and acceptability of using myo-inositol to prevent gestational diabetes in high-risk pregnant women. The study found lower HOMA-IR and serum insulin levels in the myo-inositol group compared to placebo, indicating a potential reduction in insulin resistance. Adherence was a challenge due to the powder form of the supplement and pregnancy-related nausea.
The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial.
RCT investigating the effect of myo-inositol supplementation on preventing gestational diabetes in 60 overweight pregnant women. The myo-inositol group showed a significantly reduced incidence of gestational diabetes compared to the control group.
Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomized open-label study.
Randomized open-label study comparing myo-inositol and d-chiro-inositol combination to combined hormonal contraceptive in young women with PCOS. The combination was effective in regularizing menstrual cycles and improving insulin resistance.
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
RCT comparing the effects of myoinositol and metformin on metabolic outcomes in 66 women with PCOS over 6 months. Both treatments showed similar effects on BMI, body composition, hormonal profile, and glucose metabolism, with no significant differences between them.
The effect of Myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial.
This double-blinded randomized controlled trial evaluated the effect of Myo-inositol on fertility rates in 60 poor ovarian responder women undergoing assisted reproductive technique. The intervention group received Inofolic (4g myo-inositol + 400μg folic acid) and showed higher ovarian sensitivity index and fertilization rate compared to the control group, with a significantly lower required dose of gonadotropin.
Treatment of lean PCOS teenagers: a follow-up comparison between Myo-Inositol and oral contraceptives.
RCT comparing myo-Inositol and oral contraceptives in lean teenagers with PCOS. Myo-Inositol treatment led to significant decreases in weight and BMI, and improved metabolic and hormonal parameters in both age groups studied.
Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial.
RCT comparing myoinositol plus metformin versus myoinositol alone in 116 infertile PCOS women undergoing ovulation induction. Both groups showed comparable improvements in metabolic and hormonal parameters, with clinical pregnancy rates of 42.0% and 45.5% respectively. Myoinositol alone may improve metabolic, hormonal, and reproductive outcomes in PCOS.
Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: A randomized controlled trial.
RCT evaluating myo-inositol supplementation in 112 poor ovarian responder patients undergoing ICSI. Myo-inositol improved fertilization rate and embryo quality, with potential enhancement in cumulative pregnancy rate.
The impact of myo-inositol supplementation on sleep quality in pregnant women: a randomized, double-blind, placebo-controlled study.
RCT evaluating the impact of myo-inositol supplementation on sleep quality in 60 pregnant women. Myo-inositol supplementation improved global sleep quality, subjective sleep quality, and sleep duration during pregnancy.
The effect of myo-inositol/di-chiro-inositol on markers of ovarian reserve in women with PCOS undergoing IVF/ICSI: A systematic review and meta-analysis.
Systematic review and meta-analysis evaluating the effect of inositols on ovarian reserve markers and reproductive outcomes in women with polycystic ovary syndrome undergoing IVF/ICSI. The review included 18 trials and found no significant differences between inositol and control groups for outcomes such as number of oocytes, clinical pregnancy rate, and risk of ovarian hyperstimulation syndrome. The quality of evidence was assessed as very low.
Effect of inositol and its derivatives on diabetes: a systematic review.
Systematic review of 26 studies examining the effects of inositol and its derivatives on diabetes and gestational diabetes. The review suggests inositol may improve fasting blood glucose and other biochemical parameters in diabetic individuals, but larger studies with longer follow-up are needed.
Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial.
RCT of 638 preterm infants younger than 28 weeks' gestational age testing myo-inositol for reducing type 1 retinopathy of prematurity (ROP) or death. The trial was terminated early due to higher mortality in the myo-inositol group, with no reduction in type 1 ROP or death compared to placebo.
The efficacy of myo-inositol supplementation to prevent gestational diabetes onset: a meta-analysis of randomized controlled trials.
Meta-analysis of randomized controlled trials assessing myo-inositol supplementation's effect on gestational diabetes onset. Myo-inositol supplementation is associated with a significantly reduced incidence of gestational diabetes and preterm delivery in pregnant women.
The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials.
Systematic review and meta-analysis of 14 RCTs evaluating the effects of inositol supplementation on lipid profiles in patients with metabolic diseases. Inositol supplementation significantly decreased triglycerides, total cholesterol, and LDL-cholesterol levels, but had no effect on HDL-cholesterol levels.
The Prevention of Gestational Diabetes Mellitus With Antenatal Oral Inositol Supplementation: A Randomized Controlled Trial.
RCT investigating if inositol combined with chiro-inositol prevents gestational diabetes mellitus (GDM) in women with a family history of diabetes. The study found no significant difference in the incidence of GDM between the intervention and control groups.
Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Meta-analysis of studies on inositol, specifically D-chiro-inositol and myo-inositol, as insulin-sensitizers in metabolic syndrome, type II diabetes, and polycystic ovarian syndrome. The paper concludes that these compounds counteract insulin resistance and act synergistically with other insulin-sensitizing agents, though further studies are needed to clarify outcomes and dosages.
Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial.
RCT evaluating myo-inositol supplementation in 220 overweight pregnant women to reduce gestational diabetes mellitus (GDM) incidence. Myo-inositol group showed significantly lower GDM rates compared to placebo, with a 67% risk reduction.
Inositol in preterm infants at risk for or having respiratory distress syndrome.
Meta-analysis of RCTs assessing inositol supplementation in preterm infants with or without respiratory distress syndrome. Inositol supplementation significantly reduced neonatal and infant deaths, retinopathy of prematurity, and intraventricular hemorrhage. No significant differences were found for sepsis or necrotizing enterocolitis. A large ongoing study may further validate these findings.
Preventive and Therapeutic Role of Dietary Inositol Supplementation in Periconceptional Period and During Pregnancy: A Summary of Evidences and Future Applications.
Systematic review of inositol supplementation in the periconceptional period and during pregnancy. Inositol reduces the risk of gestational diabetes mellitus in at-risk patients and improves metabolic status during pregnancy. It also prevents folate-resistant embryo neural tube defects, with no significant complications reported.
Inositol for respiratory distress syndrome in preterm infants.
Meta-analysis assessing the effectiveness and safety of inositol supplementation in preterm infants with respiratory distress syndrome. Inositol supplementation significantly reduced neonatal and infant deaths, retinopathy of prematurity, and intraventricular hemorrhage, but not sepsis or necrotizing enterocolitis.
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
Systematic review of randomized controlled trials examining the effects of myo-inositol on ovarian function and metabolic and hormonal parameters in women with PCOS. The review highlights myo-inositol's potential to restore ovarian activity and improve fertility in PCOS patients.
Inositol for depressive disorders.
Systematic review of four RCTs with 141 participants assessing inositol for depression treatment. The trials did not show clear evidence of therapeutic benefit or poor acceptability. The benefit of inositol in depression remains unclear.
Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial.
RCT of 283 women with PCOS comparing inositol to placebo. Inositol improved ovulation frequency, reduced time to first ovulation, and increased E2 levels. Significant weight loss and increased HDL were observed in the inositol group, but no changes in fasting glucose or insulin responses were noted.
Effect of Myo-Inositol Treatment on Serum Asprosin Levels of Pregnant Women: A Prospective Randomized Controlled Pilot Study.
Prospective RCT evaluating the effects of myo-inositol supplementation on serum asprosin levels in pregnant women. The study found that myo-inositol decreased serum asprosin values and improved insulin resistance indices (HOMA-IR index) compared to the control group receiving only folic acid.
Effect of 40:1 myo-inositol/D-chiro-inositol treatment on serum asprosin levels in polycystic ovary syndrome: a prospective randomized pilot study.
Prospective randomized pilot study evaluating the effects of 40:1 myo-inositol/D-chiro-inositol treatment on serum asprosin levels in 30 patients with polycystic ovary syndrome (PCOS). The study found a reduction in serum asprosin levels in both the inositol and metformin groups, with a greater decrease in the inositol group, although not statistically significant.
HMGB1 is increased in adolescents with polycystic ovary syndrome (PCOS) and decreases after treatment with myo-inositol (MYO) in combination with alpha-lipoic acid (ALA).
RCT involving 23 adolescents with PCOS treated with myo-inositol and alpha-lipoic acid for 6 months. Treatment normalized elevated HMGB1 levels, reduced insulin, HOMA-IR, and 17-hydroxyprogesterone, but did not change cholesterol, luteinizing hormone, 17-β-estradiol, delta 4-androstenedione, and testosterone.
The effect of myoinositol on ovarian blood flows in women with polycystic ovary syndrome.
RCT evaluating the effects of 4g myoinositol and 400mcg folic acid therapy on ovarian stromal blood flow in women with PCOS using Doppler ultrasound. Significant increases in resistance index and pulsatility index were observed in PCOS patients receiving myoinositol, similar to those receiving oral contraceptives. Myoinositol therapy reduced ovarian vascularization in both PCOS and healthy users after 3 months, with a more noticeable decrease in women with PCOS.
The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole.
Randomized single-blind controlled trial comparing the effectiveness of myo-inositol and metformin in 150 infertile women with PCOS resistant to letrozole. Inositol improved ovarian function more effectively than metformin in patients with normal BMI, though overall improvements were not significant.
Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial.
RCT comparing Metformin plus Myoinositol versus Metformin alone in 120 infertile PCOS women undergoing ovulation induction. The combination group showed significant improvement in menstrual cycles and a higher live birth rate compared to Metformin alone.
Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
RCT comparing two doses of D-chiro-inositol in combination with Myo-inositol in 60 women with PCOS undergoing ICSI. The study found higher pregnancy and live birth rates and a lower risk of OHSS in the group receiving higher doses of DCI.
The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.
This clinical trial evaluated the efficacy of seven different myo-inositol/D-chiro-inositol ratios in treating PCOS. The 40:1 MI/DCI ratio was found to be the most effective in restoring ovulation and normalizing hormonal parameters in PCOS patients.